arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Artiva Biotherapeutics, Inc.

ARTV

$7.70 ▼ -0.38 (-4.70%) at close

15 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Artiva Biotherapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $303.5M

Dividend Yield —

Revenue Growth —

Op. Margin None

ROIC -6.1% ↗

FCF / Share $-0.53 ↗

Trailing P/E —

Price / Book 0.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

15-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-23.52M

↓ -15.8% —

Operating Margin Operating profit as % of sales

40.6%

↑ +112.0% —

FCF / Share Free cash flow per share

$-0.53

↑ +46.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	27.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-14.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	4.3% Caution ↓ Caution Declining Year-over-year change in earnings per share Optimal: > 10%	96.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	95.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	-56.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-15.8% Weak ↑ Weak Improving Year-over-year change in net income	-15.8% Weak ↑ Weak Improving Year-over-year change in net income	-29.1% Weak ↑ Weak Improving Year-over-year change in net income	-45.5% Weak ↓ Weak Declining Year-over-year change in net income	-45.5% Weak ↓ Weak Declining Year-over-year change in net income	-45.5% Weak ↓ Weak Declining Year-over-year change in net income	-34.1% Weak ↓ Weak Declining Year-over-year change in net income	16.5% Good Good Year-over-year change in net income	16.5% Good Good Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	46.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-2.7% Weak ↓ Weak Declining Year-over-year change in free cash flow	—	-30.6% Weak ↓ Weak Declining Year-over-year change in free cash flow	94.3% Excellent → Excellent Stable Year-over-year change in free cash flow	95.5% Excellent Excellent Year-over-year change in free cash flow	—	95.4% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	40.6% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+170%)	-338.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2354%)	—	—
Profit Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	-62.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-623%)	-478.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4084%)	—	—
FCF Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	-481.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-41.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—
FCF / Net Income (x)	0.88x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.18x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.00x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.08x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.65x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-6.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-22.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-15.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-14.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	6.7% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	6.6% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	5.8% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	-5.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	5.7% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-7.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-23.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-15.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	—	-11.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-8.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	-11.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-6.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-145%)	-26.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-278%)	-18.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-226%)	-15.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-205%)	-13.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-191%)	-12.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-180%)	-8.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-157%)	-6.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-146%)	7.3% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-51%)	8.0% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-47%)	7.4% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-51%)	11.0% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-26%)	10.2% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-32%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Net Debt (USD)	$-301.45M	$-20.95M	$-26.70M	$-25.51M	$-28.47M	$-30.40M	$-40.23M	$-55.88M	$-34.25M	$-48.20M	$-53.50M	$-65.89M	$-53.70M	—	—

📊 What does each share earn? 6 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue per Share (USD)	—	—	—	—	—	—	—	$0.00	$0.00	$0.31	—	$33.04	$4.37	—	—
Basic EPS, GAAP (USD)	$-0.63	$-0.95	$-0.84	$-0.88	$-0.87	$-0.83	$1.35	$-0.92	$-22.00	$-17.24	$-14.89	$13.98	$-14.09	—	—
Free Cash Flow per Share (USD)	$-0.53	$-0.86	—	$-0.81	$-0.99	$-0.84	—	$-0.62	$-17.44	$-18.65	—	$-13.55	—	—	—
Book Value per Share (USD)	$8.82	$3.56	—	$5.28	$6.11	$6.93	—	$10.64	$-235.57	$-215.71	—	$-187.74	$-205.09	—	—
Tangible Book Value per Share (USD)	$8.82	$3.56	—	$5.28	$6.11	$6.93	—	$10.64	$-235.57	$-215.71	—	$-187.74	$-205.09	—	—
Basic Weighted Avg Shares (shares)	39.41M	24.68M	—	24.48M	24.38M	24.34M	—	18.90M	811,210	809,758	—	806,714	800,889	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$337.69M	$77.86M	$99.58M	$118.41M	—	$157.80M	$176.38M	—	—	—	$67.59M	—	—	—	—
Total Equity (USD)	$347.50M	$87.85M	$109.97M	$129.22M	$149.04M	$168.78M	$186.64M	$201.00M	$-191.10M	$-174.67M	$-162.01M	$-151.45M	$-164.25M	$-155.57M	$-140.70M

📋 What is driving earnings? 4 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	—	$0.00	$0.00	$0.00	$251.00K	$2.35M	$26.66M	$3.50M	—	—
Depreciation Expense (USD)	$692.00K	$666.00K	$666.00K	$662.00K	$641.00K	$628.00K	$614.00K	$627.00K	$603.00K	$587.00K	$594.00K	$556.00K	$500.00K	—	—
Net Income, GAAP (USD)	$-23.52M	$-23.52M	$-20.77M	$-20.31M	$-20.31M	$-20.31M	$-16.09M	$-13.96M	$-13.96M	$-13.96M	$-12.00M	$-16.72M	$-16.72M	—	—
Operating Cash Flow (USD)	$-20.36M	$-20.95M	$-14.73M	$-19.20M	$-22.98M	$-19.84M	$-14.65M	$-11.61M	$-13.69M	$-15.09M	$-10.68M	$-10.75M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 4 years · 15 quarters

Artiva Biotherapeutics, Inc.

Analytical Summary

15-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ARTV with peers